Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04918082

Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique

Cancer and its treatments can be factors that alter the quality of life of patients. The induced alteration of the quality of life can influence compliance and impact survival. Considering the after-effects of the treatment, carrying out such a survey will provide for the first time precise information on the main determinants of the quality of life as well as on the care pathway of patients with invasive breast cancer in the Martinique region.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Quality of Life Skin Diseases Skin and Connective Tissue Diseases Survivorship

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

CHU Martinique

Fort-de-France, 97261, Martinique

About this study

Breast cancer is the second most common cancer in the West Indies and the leading cancer in women. With 215 new cases in Guadeloupe, 204 in Martinique and 56 in French Guiana each year, it accounts for 37%, 33% and 26% of incident cancer cases in women respectively, but also affects men. Its incidence, lower than in France, is increasing over the period 2008-2014. The diagnostic and therapeutic management of cancer can have an impact on the quality of life of patients, taking into account the adverse effects occurring during and after treatment, both in the short and long term. The European Organisation for Research and Treatment of Cancer (EORTC) has developed a series of questionnaires to assess the quality of life of cancer patients, including a general questionnaire (QLQ-C30) and specific modules for breast cancer (EORTC BREAST (EORTC QLQ-BR23)) with the objective of improving professional practices.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years of age residing in Martinique with invasive breast cancer diagnosed from 2020 (single tumor at diagnosis)
  • Patients who have read the information note and have indicated that they do not wish to participate in the study
  • Patient with social security coverage.

Exclusion criteria

  • Refusal to participate
  • Patient with insitu breast cancer
  • Patient with a second cancer
  • Patient with cancer within 5 years prior to inclusion
  • Patient who could not answer quality of life questionnaires
  • Patient not fluent in French
  • Person under legal protection (safeguard of justice, guardianship, curators , etc.).

Treatment and study plan

Quality of life questionnaires

Other

Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.

Primary outcomes

  1. Assessment of global disorders in patients with breast cancer

    Time frame: 12 months after diagnosis

    Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-C30

  2. Assessment of disorders specific to breast cancer patients Assessment of disorders specific to breast cancer patients

    Time frame: 12 months after diagnosis

    Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-BR23

  3. Assessment of global disorders in patients with breast cancer

    Time frame: 36 months after diagnosis

    Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-C30

  4. Assessment of disorders specific to breast cancer patients

    Time frame: 36 months after diagnosis

    Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-BR23

Sponsors and collaborators

Lead sponsor

University Hospital Center of Martinique

Other

Registry information

Acronym: Qualibreast-MQ

Important dates

Study start
2020
Primary completion
2026
Study completion
2027
First posted
Jun 8, 2021
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.